186 related articles for article (PubMed ID: 31042256)
1. Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.
Vallet A; Oriano B; Mortier L; Dalle S; Dutriaux C; Guillot B; Leccia MT; Dalac S; Saiag P; Lacour JP; Legoupil D; De Quatrebarbes J; Brunet-Possenti F; Lesimple T; Arnault JP; Aubin F; Granel-Brocard F; Stoebner PE; Maubec E; Dreno B; Allayous C; Porcher R; Lebbé C;
JAMA Dermatol; 2019 Jun; 155(6):673-678. PubMed ID: 31042256
[TBL] [Abstract][Full Text] [Related]
2. Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor.
von Schuckmann LA; Hughes MCB; Ghiasvand R; Malt M; van der Pols JC; Beesley VL; Khosrotehrani K; Smithers BM; Green AC
JAMA Dermatol; 2019 Jun; 155(6):688-693. PubMed ID: 31042258
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.
Bedikian AY; Wei C; Detry M; Kim KB; Papadopoulos NE; Hwu WJ; Homsi J; Davies M; McIntyre S; Hwu P
Am J Clin Oncol; 2011 Dec; 34(6):603-10. PubMed ID: 21150567
[TBL] [Abstract][Full Text] [Related]
4. Time course and pattern of metastasis of cutaneous melanoma differ between men and women.
Mervic L
PLoS One; 2012; 7(3):e32955. PubMed ID: 22412958
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma.
Calomarde-Rees L; García-Calatayud R; Requena Caballero C; Manrique-Silva E; Traves V; García-Casado Z; Soriano V; Kumar R; Nagore E
JAMA Dermatol; 2019 Jun; 155(6):679-687. PubMed ID: 31042264
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.
Zaremba A; Philip M; Hassel JC; Glutsch V; Fiocco Z; Loquai C; Rafei-Shamsabadi D; Gutzmer R; Utikal J; Haferkamp S; Reinhardt L; Kähler KC; Weishaupt C; Moreira A; Thoms KM; Wilhelm T; Pföhler C; Roesch A; Ugurel S; Zimmer L; Stadtler N; Sucker A; Kiecker F; Heinzerling L; Meier F; Meiss F; Schlaak M; Schilling B; Horn S; Schadendorf D; Livingstone E
Eur J Cancer; 2021 Jul; 152():139-154. PubMed ID: 34102453
[TBL] [Abstract][Full Text] [Related]
7. Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma.
El Sharouni MA; Aivazian K; Witkamp AJ; Sigurdsson V; van Gils CH; Scolyer RA; Thompson JF; van Diest PJ; Lo SN
JAMA Dermatol; 2021 Feb; 157(2):166-173. PubMed ID: 33355600
[TBL] [Abstract][Full Text] [Related]
8. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia.
Velez NF; Karia PS; Vartanov AR; Davids MS; Brown JR; Schmults CD
JAMA Dermatol; 2014 Mar; 150(3):280-7. PubMed ID: 24429548
[TBL] [Abstract][Full Text] [Related]
9. Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials.
Joosse A; Collette S; Suciu S; Nijsten T; Patel PM; Keilholz U; Eggermont AM; Coebergh JW; de Vries E
J Clin Oncol; 2013 Jun; 31(18):2337-46. PubMed ID: 23690423
[TBL] [Abstract][Full Text] [Related]
10. Quality-of-life assessment in French patients with metastatic melanoma in real life.
Kandel M; Dalle S; Bardet A; Allayous C; Mortier L; Dutriaux C; Guillot B; Leccia MT; Dalac S; Legoupil D; Saiag P; Montaudie H; Arnault JP; Brunet-Possenti F; Grob JJ; DeQuatrebarbes J; Beylot-Barry M; Lesimple T; Aubin F; Maubec E; Granel-Brocard F; Stoebner PE; Dupuy A; Dreno B; Michiels S; Lebbe C; Borget I
Cancer; 2020 Feb; 126(3):611-618. PubMed ID: 31639198
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Long GV; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Kefford RF; Thompson JF; Scolyer RA
Ann Surg Oncol; 2012 Jun; 19(6):1782-9. PubMed ID: 22350600
[TBL] [Abstract][Full Text] [Related]
12. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Review of Conjunctival Melanoma Presentation, Treatment, and Outcome and an Investigation of Features Associated With BRAF Mutations.
Larsen AC; Dahmcke CM; Dahl C; Siersma VD; Toft PB; Coupland SE; Prause JU; Guldberg P; Heegaard S
JAMA Ophthalmol; 2015 Nov; 133(11):1295-303. PubMed ID: 26425792
[TBL] [Abstract][Full Text] [Related]
14. Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients.
Crookes TR; Scolyer RA; Lo S; Drummond M; Spillane AJ
Ann Surg Oncol; 2017 May; 24(5):1378-1385. PubMed ID: 28130620
[TBL] [Abstract][Full Text] [Related]
15. Association Between Lymph Node Ratio and Recurrence and Survival Outcomes in Patients With Oral Cavity Cancer.
Ding D; Stokes W; Eguchi M; Hararah M; Sumner W; Amini A; Goddard J; Somerset H; Bradley C; McDermott J; Raben D; Karam SD
JAMA Otolaryngol Head Neck Surg; 2019 Jan; 145(1):53-61. PubMed ID: 30452499
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.
Burmeister BH; Henderson MA; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF
Lancet Oncol; 2012 Jun; 13(6):589-97. PubMed ID: 22575589
[TBL] [Abstract][Full Text] [Related]
17. Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data
Di Filippo Y; Dalle S; Mortier L; Dereure O; Dalac S; Dutriaux C; Leccia MT; Legoupil D; Saiag P; Brunet-Possenti F; Arnnault JP; Maubec E; Granel-Brocard F; De Quatrebarbes J; Aubin F; Lesimple T; Beylot-Barry M; Stoebner PE; Dupuy A; Stephan A; Grob JJ; Lefevre W; Oriano B; Allayous C; Lebbé C; Montaudié H
Ann Oncol; 2021 Apr; 32(4):542-551. PubMed ID: 33385520
[TBL] [Abstract][Full Text] [Related]
18. Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy.
Sun L; Chin RI; Gastman B; Thorstad W; Yom SS; Reddy CA; Nussenbaum B; Wang SJ; Knackstedt T; Vidimos AT; Koyfman SA; Manyam BV
JAMA Dermatol; 2019 Apr; 155(4):442-447. PubMed ID: 30810715
[TBL] [Abstract][Full Text] [Related]
19. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma.
Francken AB; Accortt NA; Shaw HM; Wiener M; Soong SJ; Hoekstra HJ; Thompson JF
Ann Surg Oncol; 2008 May; 15(5):1476-84. PubMed ID: 18196345
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
